Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
Afsane BahramiSeyed Mahdi HassanianSoodabeh ShahidSalesZahra FarjamiMalihe HasanzadehKazem AnvariAmir AledavoodMina MaftouhGordon A FernsSoodabeh ShahidsalesAmir AvanPublished in: Journal of cellular physiology (2017)
The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently dysregulated in colorectal cancer (CRC). It is involved in the modulation of several downstream effectors, that include: Raf/Mek/Erk, PI3K/Akt, RalGDS/p38MAPK, and Rac/Rho, and thereby influences tumorigenesis, the invasive behaviors of tumor cell, and resistance to therapy. There is growing evidence exploring the use of drugs that target these pathways in the treatment of CRC. Cetuximab has been approved for CRC patients without a KRAS mutation, or for EGFR-expressing metastatic CRC, although some of the patients have a mutation of KRAS and NRAS. This review summarizes the recent knowledge about the therapeutic potential of targeting RAS with particular emphasis on recent preclinical and clinical studies in treatment of CRC.
Keyphrases
- pi k akt
- wild type
- signaling pathway
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- prognostic factors
- healthcare
- peritoneal dialysis
- squamous cell carcinoma
- cell proliferation
- sars cov
- cell death
- risk assessment
- cell cycle arrest
- radiation therapy
- neoadjuvant chemotherapy
- tyrosine kinase
- climate change
- bone marrow
- induced apoptosis
- smooth muscle
- cell migration
- patient reported
- drug induced